Enliven Therapeutics
ELVN
46.53
+0.12
+0.26%
Enliven Therapeutics
US · ELVN
#2416 by market cap
Listed 1970
46.53
+0.12
+0.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
William Blair Maintains Enliven Therapeutics(ELVN.US) With Buy RatingMarket Newswire · 2026/10/7
-
Rating change
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73Market Newswire · 2026/8/18
-
Rating change
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64Market Newswire · 2026/7/9
-
Rating change
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy RatingMarket Newswire · 2026/10/8
-
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $73Market Newswire · 2026/11/13
-
Rating change
J.P. Morgan Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $75Market Newswire · 2026/10/1
-
Rating change
Morgan Stanley Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/10/5
-
Rating change
William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy RatingMarket Newswire · 2026/8/18
-
Rating change
Morgan Stanley Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $70Market Newswire · 2026/10/2
-
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/11/7
-
Barclays Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/11/5
-
Rating change
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73Market Newswire · 2026/10/19
-
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82Market Newswire · 2026/11/6
-
Rating change
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82Market Newswire · 2026/8/7
-
Rating change
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/8/8
-
Rating change
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/8/8
-
Rating change
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80Market Newswire · 2026/7/1
-
Rating change
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67Market Newswire · 2026/7/22
-
Guggenheim Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/11/6
-
Rating change
Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78Market Newswire · 2026/8/18
-
Barclays Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/10/7
-
Rating change
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $45 to $80Market Newswire · 2026/6/12
-
Rating change
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/6/29
-
Rating change
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/6/15
-
Rating change
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82Market Newswire · 2026/8/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Enliven Therapeutics discussion 0 comments